MDxHealth ( (MDXH) ) has issued an update.
On February 26, 2025, Mdxhealth announced its financial results for the fourth quarter and full year of 2024, highlighting a 28% revenue growth to $90 million for the year. The company reported a significant improvement in adjusted EBITDA and a decrease in net loss, driven by increased demand for its precision diagnostics and strategic market penetration in the urology sector. The results underscore Mdxhealth’s commitment to sustainable growth and its strengthened financial position, setting the stage for profitability in 2025 and continued value delivery to stakeholders.
More about MDxHealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The company specializes in tests based on proprietary genomic, epigenetic (methylation), and other molecular technologies, assisting physicians in diagnosing and prognosing urologic cancers and other diseases. Mdxhealth operates its U.S. headquarters and laboratory in Irvine, California, with additional operations in Plano, Texas, and its European headquarters in Herstal, Belgium.
YTD Price Performance: -15.22%
Average Trading Volume: 102,945
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $96.52M
For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com